EKF Diagnostics will be at the 2022 AACC Clinical Lab Expo, Chicago IL, on 26–28 July, exhibiting its range of laboratory and point-of-care diagnostics products.
These include the FDA-cleared Lucica Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the USA by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate-term monitoring of glycaemic control in diabetes patients.
Lucica Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analysers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions, and the results are expressed as a ratio (%), minimising differences in albumin concentrations between patients. Lucica is also standardised to an established reference material.
Alongside its range of clinical chemistry tests and diagnostics analysers, also available to view will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analysers and associated data on one centralised platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure and effective POC testing using analysers in many differing locations.